Foratec

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Foratec

What is Foratec? Definitive Classification and Factual Identity

Property Description
Active Ingredient Formoterol fumarate
Form Inhalation Powder or Aqueous Solution
Pharmacological Class Long-Acting Beta-Agonist (LABA)
General Purpose Sustained widening of airways (Bronchodilation)
Origin Synthetic compound

I. Defining Foratec: Classification and Core Identity

Foratec is a specific prescription pharmacological preparation whose active component is the substance Formoterol, delivered as the fumarate salt. It is formally classified as an Adrenergic Beta-2 Receptor Agonist and, more specifically, a Long-Acting Beta-Agonist (LABA). This classification defines the medicine's core function as selectively stimulating the beta-2 receptors found on the smooth muscles of the respiratory tract.

The designation of Formoterol as a LABA is derived from its chemical structure, which enables it to exert a sustained bronchodilator effect for up to twelve hours. This extended duration of action is clinically recognized and differentiates it from short-acting inhalers, making it primarily intended for maintenance treatment.

II. Composition and Form: The Formoterol Fumarate Entity

The core substance is the International Nonproprietary Name (INN) Formoterol fumarate, delivered as a single-entity synthetic product. This engineered compound is strictly formulated for the Oral Inhalation route of administration, maximizing its therapeutic effect directly within the lungs.

Foratec is typically supplied in one of two high-level dosage forms: either as a fine powder intended for use with a dedicated dry powder inhaler device or as an Aqueous Solution designed for nebulization. This choice in formulation allows for administration across different patient needs.

III. General Purpose: Sustained Airway Support

The fundamental, general therapeutic purpose of this medicine is to promote bronchodilation, which involves the relaxation of the bronchial smooth muscle. This action reliably counteracts the chronic constriction of the airways.

By maintaining the relaxed state of the air passages over an extended duration, the medicine provides sustained airway widening. The resulting benefit is the significant enhancement of air flow, which supports easier, more consistent breathing throughout the day and night for the intended patient population.

What side effects are possible with Foratec?

Adverse Reactions and Safety Profile

The safety profile for Foratec, based on regulatory documentation, details adverse reactions by frequency and specifies important restrictions for use.

Adverse Reaction Categories

Clinical trials identify pain in the arms or legs (arthralgia/pain in extremity) as the most common adverse reaction, classified as Very Common (occurring in more than 1 in 10 patients). Other reported side effects may involve the nervous system, musculoskeletal system, and gastrointestinal tract.

Classification System-Organ Class Involved
Very Common Musculoskeletal and connective tissue disorders
Common (May include) Central nervous system, Gastrointestinal disorders

Serious and Clinically Significant Safety Considerations

The use of Foratec is contraindicated and requires specific safety monitoring in several patient populations due to the potential for serious outcomes. The drug is a parathyroid hormone analog and has specific risks related to bone and calcium metabolism.

Contraindicated Populations and Conditions:

  • Patients with other metabolic bone diseases besides the indicated use, such as Paget's disease.
  • Patients with bone metastases or a history of skeletal malignancies (bone cancer).
  • Patients who have previously undergone radiation therapy to the skeleton.
  • Patients with hypercalcaemia (elevated blood calcium levels).
  • Children and young adults whose bones are not yet fully mature (open epiphyses).
  • Pregnancy and breastfeeding are considered contraindications for use.

Regulatory and Monitoring Notes:

Official prescribing information often mandates caution in patients with active or recent urolithiasis (kidney stones) due to the risk of exacerbation. Transient orthostatic hypotension (a sudden drop in blood pressure upon standing) may also be observed with initial doses. As a prescription-only medicine, patient training on the correct self-administration technique is a critical safety component defined in regulatory documents.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Foratec (Formoterol fumarate) is defined by the consequences of excessive beta-adrenergic stimulation, as documented in government regulatory labeling. Excessive use or administration at higher than recommended doses may result in overdose.


Documented Overdose Manifestations

Manifestations are an exaggeration of Formoterol's pharmacological effects. Symptoms and clinical signs formally listed in regulatory documents include:

System Documented Manifestations
Cardiovascular Tachycardia (fast heart rate, up to 200 beats/min reported), Palpitation, Arrhythmias, Angina, Hypertension, or Hypotension.
CNS Tremor, Nervousness, Headache, Insomnia, Dizziness, and Seizures.
Metabolic Hypokalemia (low serum potassium), Hyperglycemia (high blood glucose), and Metabolic acidosis.

Severe Outcomes and Required Actions

Official labeling explicitly states that excessive use of Formoterol can result in clinically significant cardiovascular effects and may be fatal. Because of this risk, mandatory actions are required:

  • Seek Immediate Help: Patients must seek immediate medical attention and contact emergency services if the recommended dose of Foratec is exceeded.
  • Management: Treatment is symptomatic and supportive, requiring discontinuation of the product.
  • Monitoring: Cardiac monitoring is recommended in all cases of suspected overdose. The judicious use of a cardioselective beta-receptor blocker may be considered by healthcare professionals, with caution regarding potential bronchospasm. No specific antidote is documented.

Therapeutic Uses of Foratec

Main Uses of Foratec

Foratec is a long-acting bronchodilator used for the long-term management of respiratory conditions characterized by airflow obstruction. Its primary role is to help keep the airways open over an extended period, making it easier for patients to breathe.

Chronic Obstructive Pulmonary Disease (COPD)

Foratec is indicated for the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. In these conditions, the airways become damaged or clogged with mucus, leading to persistent shortness of breath. By relaxing the smooth muscles in the lungs, the medication helps reduce these symptoms and improves daily lung function.

Asthma Management

In the treatment of asthma, Foratec is used as an add-on therapy for patients whose symptoms are not sufficiently controlled by long-term asthma control medications, such as inhaled corticosteroids. It is intended for regular, long-term use to prevent symptoms like wheezing and chest tightness. It is important to note that this medication is used for maintenance and is not designed to treat sudden, acute attacks of breathlessness.

Benefits of Treatment

Sustained Bronchodilation

One of the primary benefits of Foratec is its long duration of action. After inhalation, the medication begins to work relatively quickly and continues to keep the bronchial tubes dilated for approximately 12 hours. This long-lasting effect provides a stable level of airway clearance throughout the day and night.

Improved Quality of Life

By providing consistent control over respiratory symptoms, Foratec can help patients engage more effectively in physical activities and daily routines. Improved breathing capacity often leads to better sleep patterns and a reduction in the frequency of chronic coughing and wheezing.

Prevention of Exercise-Induced Bronchospasm

Foratec may also be used to prevent bronchospasm triggered by physical exertion. When used for this purpose, it helps protect the airways from narrowing during exercise, allowing patients to maintain an active lifestyle without immediate respiratory distress.

Regulatory References

  1. NIH DailyMed label

Eligibility and Restrictions for Use

This section outlines the eligibility and non-eligibility criteria for Foratec (formoterol), strictly based on authoritative government regulatory documents.

Populations Allowed and Not Allowed

The medicine is primarily indicated for patients with Chronic Obstructive Pulmonary Disease (COPD) and for the long-term maintenance treatment of asthma.

Classification Population/Condition
Contraindicated Use as monotherapy for asthma (without a concomitant inhaled corticosteroid, or ICS). Patients with a known hypersensitivity to formoterol or any component of the product.
Not Indicated Treatment of acute episodes of bronchospasm or rapidly deteriorating COPD/asthma (must not be used as rescue therapy).

Eligibility Constraints

Official labeling requires special caution or consideration for certain patient groups:

  • Pediatric Use: Safety and efficacy have not been established in children younger than 5 years of age for inhalation powder formulations, and for inhalation solutions, it is often not indicated for the pediatric population.
  • Existing Conditions: Use with caution in patients with cardiovascular disorders, including cardiac arrhythmias, hypertension, or in those with thyrotoxicosis.
  • Other Restrictions: Patients must not use Formoterol in conjunction with other long-acting beta2-agonists (LABAs).

What should I know about interactions with other medicines?

Interaction Scope and Restrictions

The officially documented interaction profile for Formoterol fumarate involves several pharmacological classes. A formal prohibition exists against the co-administration of Foratec with other Long-Acting Beta-Agonists (LABA) due to the potential risk of overdose and significant cardiovascular effects. Furthermore, use as monotherapy (without an inhaled corticosteroid) is contraindicated for the treatment of asthma.

Pharmacodynamic and Exposure Patterns

Co-administration with Monoamine Oxidase (MAO) Inhibitors, Tricyclic Antidepressants, or QTc Prolonging Drugs requires extreme caution, as these medicines may potentiate the cardiovascular effects of Formoterol, increasing the risk of ventricular arrhythmias. Conversely, Beta-blockers may reduce the drug’s intended bronchodilatory effectiveness and potentially cause severe bronchospasm. Xanthine Derivatives, Steroids, and Non-Potassium-Sparing Diuretics may potentiate the hypokalemic effect and associated ECG changes. Official documentation notes that Formoterol's systemic exposure may increase in patients with severe hepatic impairment due to reduced clearance. Caution is also advised regarding dry powder formulations containing lactose for individuals with a known milk protein allergy.

Connection to the overall interaction profile

Regulatory documents define the interaction structure by detailing constraints related to both pharmacodynamic synergy and antagonism. The profile is anchored by mandatory class-based prohibitions and by a population-specific pharmacokinetic caution addressing the risk of increased exposure in severe hepatic impairment.

Mechanism of Action

The mechanism of Formoterol fumarate is defined by its selective action on receptors and subsequent modulation of intracellular signaling pathways that control smooth muscle tone.

Selective beta2-Receptor Agonism

The molecule acts as a full agonist at the beta2-Adrenergic Receptor (beta2-AR), a G-protein coupled receptor situated on bronchial smooth muscle cells. This targeted interaction initiates a signaling cascade via the Gs protein, marking the initiation of the molecular process leading to smooth muscle relaxation.

Intracellular Second Messenger Cascade

Receptor activation rapidly accelerates the Cyclic AMP (cAMP) second messenger pathway, leading to the activation of Protein Kinase A (PKA). This biochemical sequence ultimately results in the functional reduction of intracellular calcium ions ( Ca^2+) and inhibition of the enzyme responsible for muscle contraction, resulting in the physiological state of muscle relaxation.

⏱️ Mechanism of Sustained Engagement

Formoterol's moderate lipophilicity allows it to dissolve and reside within the smooth muscle cell's lipid membrane, creating a localized drug depot. This physical mechanism ensures the molecule is continuously, slowly released to re-engage the beta2-AR, resulting in sustained pathway modulation for an extended duration.

Dosage and Administration Information

How to Use Foratec: Administration Guidelines

Foratec (Formoterol fumarate) is prescribed for long-term maintenance treatment and must be used strictly according to the provided instructions. It is an inhaled product and is not to be used for the immediate relief of acute symptoms or sudden breathing difficulty.


Established Route and Dosage

The established route of administration for Foratec is Oral Inhalation. It is available in two main forms, each requiring a specific device for proper delivery:

  • Inhalation Solution: Supplied in a unit-dose vial, often 20 mcg/2 mL, intended exclusively for use with a standard jet nebulizer.
  • Inhalation Powder: Supplied in capsules or as a reservoir, often as a 12 mcg dose, intended for use with a dedicated dry powder inhaler (DPI) device.

Standard Schedule and Maximum Dose

Foratec is intended for consistent, sustained support and is administered on a twice-daily basis, typically every 12 hours. The total dose administered must not exceed the maximum daily allowance specified on the product label. For example, the maximum total daily dose for the 20 mcg/2 mL inhalation solution is 40 mcg.


Key Administration Instructions

Contextual Instruction Practical Requirement
Preparation The inhalation solution must not be mixed with any other medicines in the nebulizer cup.
Handling Inhalation Powder capsules are not to be swallowed orally; they are for inhalation only.
Population Use The 20 mcg/2 mL inhalation solution is not recommended for use in children. No dose adjustment is typically needed for older adults.

If a dose is missed, it should be skipped, and the patient should resume the next dose at the regular time; a double dose should not be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Foratec


Evidence for Maintenance Use in Chronic Obstructive Pulmonary Disease (COPD)

Research examining Foratec for individuals with Chronic Obstructive Pulmonary Disease (COPD) relies primarily on short-term Randomized Controlled Trials (RCTs), where the medicine was evaluated in adult populations with confirmed airflow limitations. These trials and subsequent systematic reviews explored short-term changes in symptoms and lung function.

Researchers primarily studied outcomes related to pulmonary function, specifically measuring the Forced Expiratory Volume in 1 second (FEV1), and monitored patient-reported outcomes describing perceived discomfort, including scores for breathlessness and chest tightness. The research also monitored outcomes describing episodic or acute changes, such as the risk of COPD exacerbations.

In these research scenarios, studies reported patterns related to airflow measurements when compared to the measurements recorded for placebo groups over the study period. Studies report how respiratory symptoms evolved in the observed populations over the short term. Findings described patterns observed in the studies related to changes in the need for rescue medication use. Studies reported measurements of exacerbation frequency, and findings were heterogeneous across different trial settings.


Research Context for Use in Persistent Asthma

The evidence base for Foratec in persistent asthma is framed by specific regulatory guidance. Formoterol was studied for asthma, but major clinical guidelines do not support its use as a single agent (monotherapy) for daily maintenance. The research examined formoterol primarily as a component within a fixed-dose combination product alongside an inhaled corticosteroid (ICS).

Key outcomes monitored included those capturing phases of heightened symptom activity, such as the frequency of severe exacerbations and related hospitalizations. Research provides insight into short-term changes in asthma control when the medicine is used in this combination context, and studies report that symptoms evolved in the observed populations regarding exacerbation frequency.


Key Limitations and Areas of Research Uncertainty

The overall evidence landscape for formoterol features important gaps and limitations. Comparative evidence is lacking for direct, head-to-head trials against every alternative long-acting bronchodilator. A key limitation is that the medicine was observed in some studies to be associated with safety concerns when used alone for asthma maintenance; this means the current body of research reflects a mandated restriction, with little modern evidence exploring monotherapy for asthma. Consequently, the certainty remains low for certain questions, and long-term outcomes related to disease evolution and survival are not fully established.

Key Studies & References A meta-analysis of formoterol as a controller therapy for asthma

Frequently Asked Questions (FAQ)

Common questions about Foratec (FAQ)


Q: How quickly can I expect to notice any effects from Foratec?

Official documentation indicates the drug has a rapid onset of action, with effects observed within minutes of inhalation. While the relief begins quickly, Foratec is classified as a long-acting medicine because its therapeutic effects are designed to be sustained for up to 12 hours.


Q: Can Foratec be used by people who have liver problems?

Official information indicates that caution is required, particularly for individuals with severe hepatic impairment (severe liver problems). Since the drug is processed primarily by the liver, there is a potential for greater amounts of the medicine to remain in the system. Use is generally considered only if the potential benefit is judged to outweigh the possible risks associated with increased exposure.


Q: Can people with kidney issues use Foratec?

Official information indicates that for patients with mild to moderate renal impairment (kidney issues), use at the recommended dose is generally acceptable. For those with severe renal impairment or individuals undergoing dialysis, caution is advised. In these situations, use is typically considered only if the expected health benefit is greater than any potential risk.


Q: Can Foratec be used while breastfeeding?

Official regulatory documents, including product labels from the US and EU, classify breastfeeding as a contraindication, meaning its use is not permitted in patients who are breastfeeding.


Q: Is Foratec safe for children or teenagers?

The eligibility for use is determined by the specific product formulation and its approved age range. Generally, the medicine is often not indicated for children younger than 5 years of age. For inhalation solution forms, it is frequently not indicated for the pediatric population. Certain combination products have established use for asthma in patients 12 years of age and older.


Q: What groups of patients were included in the main Foratec studies?

Research supporting the use in Chronic Obstructive Pulmonary Disease (COPD) primarily included adult patients with confirmed airflow limitations. Studies related to asthma use mainly examined formoterol as a component within a fixed-dose combination product alongside an inhaled corticosteroid in patients 12 years of age and older.


Q: Does Foratec need to be taken at a specific time of day?

The standard schedule for this long-term maintenance treatment is twice daily. Official administration instructions recommend administering the doses approximately every 12 hours, typically in the morning and evening.


Q: Can Foratec cause weight changes or appetite issues?

Official adverse reaction lists do not specifically name weight gain or appetite changes as side effects. However, the medicine has been observed to cause metabolic changes like an increase in blood glucose (hyperglycemia), which may be noted in official safety information.


Q: Is it true that Foratec can cause stomach upset?

Regulatory documents list Gastrointestinal disorders as a general category in the adverse reaction profile. Specific effects noted in clinical trials include symptoms such as nausea, vomiting, diarrhea, and dry mouth.


Q: Are there any common foods or drinks that should be avoided while using Foratec?

Official interaction data advises caution with excessive consumption of caffeine-containing foods or beverages due to its potential to enhance the drug's cardiac effects, such as increasing the heart rate. Individuals who are sensitive to caffeine may be advised to limit their intake.


Q: Does Foratec affect the ability to drive or operate machinery?

Reported side effects include effects on the Central Nervous System (CNS) such as dizziness, tremor, and nervousness. The official product information advises that if a patient experiences such effects, their ability to drive or use machinery may be temporarily affected.


Q: What happens if I forget to take Foratec sometimes?

The administration guidelines state that if a dose is missed, it should simply be skipped. The official instruction is to resume the next dose at the regular scheduled time and explicitly states that a double dose should not be taken to compensate.


Q: How long is Foratec typically prescribed for?

Foratec is officially indicated for long-term, twice daily administration in the maintenance treatment of bronchoconstriction. It is intended for ongoing, sustained airway support and is not typically prescribed for short-term use.


Q: Can Foratec affect sleep patterns?

Official adverse reaction lists commonly include insomnia (trouble sleeping) and nervousness as Central Nervous System side effects that may occur.


Q: Why does Foratec come with a safety warning about certain pre-existing conditions?

Safety warnings are included because the medicine may cause clinically significant changes in the body. This includes the potential for changes in heart rate or blood pressure, or effects on blood glucose and potassium levels, which are especially important for patients with existing heart conditions or diabetes.


Q: Is Foratec an addictive medicine?

No. Formoterol fumarate, the active ingredient in Foratec, is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or equivalent international regulatory bodies.


Q: Why is Foratec only available by prescription?

The prescription-only status is due to the medicine’s classification, the need for medical diagnosis, risk management (e.g., serious asthma-related events), and the necessity of proper patient training on the correct inhalation technique.


Q: Is it possible for Foratec to suddenly stop working?

Official warnings state that a failure to provide the usual response or an increasing need for rescue inhalers can be a signal of disease deterioration. If this occurs, regulatory warnings state that medical attention should be sought for a re-evaluation of the treatment regimen.


Q: Are there any activities or sports restricted while using Foratec?

The World Anti-Doping Agency (WADA) permits inhaled use up to a specific maximum delivered dose over 24 hours for competitive sports. Doses exceeding this maximum may require documentation for approval.


Q: Do regulatory agencies classify Foratec as a controlled substance?

No. Formoterol fumarate is not classified as a controlled substance by the US Drug Enforcement Administration (DEA) or equivalent international regulatory bodies, and is regulated only as a prescription drug.


Q: How is Foratec's effectiveness measured in clinical trials?

Effectiveness in clinical trials for conditions like COPD and asthma is primarily measured by changes in pulmonary function. Key measurements include the Forced Expiratory Volume in 1 second (FEV1) and monitoring how patients report their symptoms, such as breathlessness.


Q: Can Foratec be taken on an empty stomach?

Official administration instructions do not specify a requirement to take the medicine with food or on an empty stomach. Since the medicine is administered by inhalation, it typically does not have significant food-related systemic absorption restrictions.


Q: Are there any known interactions between Foratec and caffeine?

Yes, official interaction data advises caution with caffeine consumption as it may enhance the drug’s cardiac effects, such as increasing the heart rate. Individuals who are sensitive to caffeine may be advised to limit their intake.


Q: Why is Foratec sometimes prescribed in combination with other medicines?

For the treatment of asthma, Formoterol is often prescribed in combination with an inhaled corticosteroid (ICS). This is because using Formoterol alone (monotherapy) for asthma maintenance is contraindicated due to the association observed in some studies with an increased risk of serious asthma-related events.


Q: Are there any genetic factors that might affect how Foratec works?

Official drug labels note that Formoterol is metabolized by certain enzymes, specifically CYP2D6 and CYP2C19. The drug labels state that the effect of deficiencies in these metabolizing enzymes on the drug's systemic exposure and adverse effects is not fully established.


Q: What kind of research was done to support the use of Foratec?

Research supporting the use of Formoterol for COPD relies primarily on short-term, placebo-controlled Randomized Controlled Trials (RCTs) conducted in adult populations. For asthma, research primarily examined the medicine as a component within fixed-dose combination products alongside an inhaled corticosteroid.

How should Foratec be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory guidelines for storing Foratec vary based on the product format (Solution for Nebulisation vs. Metered Dose Inhaler/Dry Powder).

Product Format Mandatory Storage Temperature Prohibited Conditions
Respules (Solution) Refrigerated (2 C to 8 C) Do not freeze.
Inhaler (MDI/Powder) Do not store above 25 C Do not refrigerate or freeze.

All Foratec products must be kept in their original containers and stored out of reach of children and pets. The individual respule solution must be used immediately after opening. Inhaler canisters are pressurized and must not be punctured, broken, or burned, even when empty, nor exposed to temperatures above 50 C. Unused or expired medicine should be disposed of by taking it to an authorized drug take-back location or by mixing it securely with undesirable material for disposal in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Foratec found in:

A-Z Index: